Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.56 |
| ▸ | LCK | P06239 | 7/20 | 0.56 |
| ▸ | SRC | P12931 | 7/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479597 | 0.95 | KDR (0.57) | KDRLCKSRCMAPK14EPHA2 | |
| SCHEMBL6478952 | 0.83 | KDR (0.74) | KDRLCKSRCMAPK14EPHB4 | |
| SCHEMBL6479352 | 0.82 | KDR (0.54) | KDRLCKSRCMAPK14EPHB4 | |
| SCHEMBL6479263 | 0.82 | SYK (0.57) | KDRLCKSRCMAPK14SYK | |
| SCHEMBL6607258 | 0.82 | SYK (0.43) | KDRLCKSRCMAPK14SYK | |
| SCHEMBL6600560 | 0.77 | PDE2A (0.40) | KDRSRCSYKEPHA2EPHB4 | |
| SCHEMBL6482909 | 0.77 | SRC (0.52) | KDRLCKSRCMAPK14SYK | |
| SCHEMBL14380859 | 0.76 | KDR (0.51) | KDRLCKSRCMAPK14EGFR | |
| SCHEMBL14380866 | 0.74 | KDR (0.57) | KDRLCKSRCMAPK14SYK | |
| SCHEMBL6492567 | 0.74 | LCK (0.60) | KDRLCKMAPK14EPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | KDR 4/4885LCK 1859/4885SRC 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.